

# 范星星



職稱	助理教授
學院/部門	中藥質量研究國家重點實驗室
電郵地址	xxfan@must.edu.mo
辦公室	H836
郵寄地址	澳門氹仔偉龍馬路科技大學 H座 836 室

## 教研領域

研究方向：分子藥理，癌症機理，癌症免疫

## 學歷

2011-2014	澳門科技大學/中藥學/博士學位
2007-2010	天津醫科大學/病原生物學/碩士學位
2002-2007	天津醫科大學/臨床醫學/學士學位

## 教學經歷

2014-2017	澳門科技大學中藥質量研究國家重點實驗室博士後
-----------	------------------------

## 學術成果

期刊文章 (\*corresponding author(s); #contribution equally)

1. **Fan XX<sup>#</sup>**, Pan HD<sup>#</sup>, Li Y, Guo RJ, Leung EL<sup>\*</sup>, Liu L<sup>\*</sup>. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. *Pharmacol Ther.* 2018 Jun 25. pii: S0163-7258(18)30112-8.

2. Li RZ<sup>#</sup>, Fan XX<sup>#</sup>, Duan FG, Jiang ZB, Pan HD1, Luo LX, Zhou YL, Li Y, Yao YJ, Yao XJ, Leung EL<sup>\*</sup>, Liu L<sup>\*</sup>. Proscillarin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation. *Cell Death Dis.* 2018 Jun 13;9(6):696.
3. Li RZ, Fan XX, Shi DF, Zhu GY, Wang YW, Luo LX, Pan HD, Yao XJ, Leung EL, Liu L. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC). *Chem Biol Drug Des.* 2018 Jun 21.
4. Fan XX<sup>#</sup>, Leung EL<sup>#</sup>, Luo LX, Jiang ZB, Zhou YL, Kam R.K. and Liu L<sup>\*</sup>. Suppression of lipogenesis via ROS/ AMPK signaling for treating malignancy and over proliferative diseases. *Antioxid Redox Signal.* 2017 Aug 4.
5. Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ, Leung EL<sup>\*</sup>, Liu L<sup>\*</sup>. *Front Pharmacol.* 2017 Apr 11;8:199.
6. Law BYK, Gordillo-Martínez F, Qu YQ, Zhang N, Xu SW, Coghi PS, Mok SWF, Guo J, Zhang W, Leung ELH, Fan XX, Wu AG, Chan WK, Yao XJ, Wang JR, Liu L<sup>\*</sup>, Wong VKW<sup>\*</sup>. Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death. *Oncotarget.* 2017 May 2;8(18):30077-30091.
7. Li X<sup>#</sup>, Fan XX<sup>#</sup>, Jiang ZB, Loo WTY, Yao XJ, Leung EL<sup>\*</sup>, Chow LWC<sup>\*</sup> & Liu L<sup>\*</sup>. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. *Pharm Res.* 2017 Jan 115: 45-55.
8. Huang J<sup>#</sup>, Fan XX<sup>#</sup>, He JX, Pan H, Li RZ, Huang LY, Jiang ZB, Yao XJ, Liu L, Leung EL<sup>\*</sup> & He JX<sup>\*</sup>. SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. *Oncotarget.* 2016 Jun 28; 7 (26): 39970-39979.
9. Wang MF, Li RZ, Li Y, Cheng XQ, Yang J, Chen W, Fan XX, Pan HD, Yao XJ, Ren T, Qian X, Liu L, Leung EL<sup>\*</sup>, Tang YJ<sup>\*</sup>. Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population. *J Thorac Dis.* 2016 Aug;8(8):2203-11.

10. Jiang JB<sup>#</sup>, Huang J<sup>#</sup>, Xie C, Li X, Liu L, He J, Pan H, Huang L, **Fan XX**, Yao XJ, Xie Y, Li N, Liu L, He JX<sup>\*</sup> & Leung EL<sup>\*</sup>. Combined use of PI3k and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutation. *Oncology Reports*. 2016 Jul; 36(1):365-75.
11. Xu SW, Law BY, Mok SW, Leung EL, **Fan XX**, Coghi PS, Zeng W, Leung CH, Ma DL, Liu L, Wong VK<sup>\*</sup>. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. *Int J Oncol*. 2016 Oct; 49(4):1576-88.
12. Zhang YZ<sup>#</sup>, Chen X<sup>#</sup>, **Fan XX**, He JX, Huang J, Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, Liu L<sup>\*</sup> & Leung EL<sup>\*</sup>. Compound library screening identified cardiac glycoside digitoxin as effective growth inhibitor of gefitinib-resistant non-small cell lung cancer via downregulation of a-tubulin and inhibition of microtubule formation. *Molecules*. 2016 Mar 18; 21(3).
13. **Fan XX**, Yao XJ, Xu SW, Wong VKW, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam R.K., Liu L<sup>\*</sup>, Leung EL<sup>\*</sup>. (Z) 3, 4, 5, 4'-Trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinib-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. *Sci Reports*. 2015 Nov 6; 5:16348.
14. Leung EL, **Fan XX**, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin PC, Liu L<sup>\*</sup>. Targeting tyrosine kinase inhibitor resistant non-small-cell lung cancer by inducing EGFR degradation via methionine 790 oxidation. *Antioxid Redox Signal*. 2016 Feb 10;24(5):263-79.
15. Yuan ZW, Leung EL, **Fan XX**, Ma WZ, Liu L, Xie Y<sup>\*</sup>. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC-MS/MS. *Talanta*. 2015 Nov 1; 144: 20-8.
16. **Fan XX**, Li N, Wu JL, Zhou YL, He JX, Liu L and Leung EL<sup>\*</sup>. Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation. *Molecules*. 2014 Mar 21; 19(3):3508-22.